Omlonti (omidenepag isopropyl) / Santen, Ube Corp - LARVOL DELTA

Effects of Topical Omidenepag Isopropyl on Intraocular Pressure and Pupil Diameter in Normal Dogs. (PubMed, Vet Ophthalmol) - "Once-daily administration of 0.002% OMDI resulted in a robust reduction in IOP without inducing miosis and was well-tolerated in normal dogs. Further studies are warranted to assess its therapeutic potential and long-term safety in dogs with glaucoma."

Clinical • Journal • Glaucoma • Ophthalmology

Delayed-Onset Cystoid Macular Edema Associated with Omidenepag Isopropyl in a Phakic Eye with Prior Trabeculectomy: A Case Report. (PubMed, Korean J Ophthalmol) - No abstract available

Journal • Macular Edema • Ophthalmology

Omidenepag isopropyl (Omlonti) for glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Intraocular Pressure-Lowering Effect of Omidenepag Isopropyl as a Predictor for the Efficacy of Laser Trabeculoplasty. (PubMed, J Glaucoma) - "A greater IOP-lowering response to OMDI predicts a larger IOP reduction with PLT, supporting the use of OMDI responsiveness as a potential indicator of PLT efficacy in POAG. OMDI administration did not alter the IOP-lowering effects of PLT."

Journal • Glaucoma • Ophthalmology

"Letter to the Editor: Myopic Shift Induced By Omidenepag Isopropyl 0.002% in Patients With Primary Open-Angle Glaucoma, Jan 2026. (PubMed, J Glaucoma) - No abstract available

Journal • Glaucoma • Ophthalmology

Five-year outcome of omidenepag isopropyl in primary open angle glaucoma and preperimetric glaucoma (ARVO 2026) - "Also, OMDI showed insignificant IOP lowering effects when switched to from OMDI, it was just maintained. These data suggest OMDI can be used as the first-line medication for patients with glaucoma."

Cataract • Glaucoma • Ophthalmology

Drug-induced cataract: a real-world study based on the food and drug administration adverse event reporting system database. (PubMed, Front Med (Lausanne)) - "The highest-risk drugs identified were omidenepag isopropyl, clobazam, and nitisinone, with BCPNN scores of 7.69, 7.36, and 6.02, respectively. The majority of affected individuals were female (67.59%) and elderly (mean age 63.85 ± 14.54 years). This study provides real-world evidence regarding the risk of drug-induced cataract, offering empirical support for preventive strategies and informed clinical decision-making."

Adverse events • Journal • Real-world evidence • Cataract • Ophthalmology

Five-Year Outcomes of Omidenepag Isopropyl Monotherapy for Untreated Primary Open-Angle Glaucoma. (PubMed, Cureus) - "This retrospective study suggests that OMDI may be a reliable first-line treatment option for glaucoma. These findings require confirmation in prospective multicenter trials."

Journal • Monotherapy • Allergy • Cataract • Glaucoma • Immunology • Ophthalmology

Diffuse bilateral macular edema associated with omidenepag isopropyl in phakic eyes after laser iridotomy: a case report. (PubMed, Jpn J Ophthalmol) - " We report a case of diffuse bilateral macular edema development after omidenepag isopropyl use in a patient with glaucoma who had undergone bilateral laser peripheral iridotomy. This case demonstrates that macular edema can develop following the use of omidenepag isopropyl, even in phakic eyes. Notably, unlike most previous reports where the edema was typically cystoid in nature, this case showed diffuse retinal thickening with a preserved retinal contour. Given diffuse macular edema may affect the measurement of circumpapillary retinal nerve fiber layer (cpRNFL) thickness, caution is warranted whenever the use of omidenepag isopropyl in the management of glaucoma is considered."

Journal • Glaucoma • Macular Edema • Ophthalmology • PTGER2

Topical Omidenepag Isopropyl Lowers Intraocular Pressure in Normal and Glaucomatous Cats: A Pilot Study. (PubMed, Vet Ophthalmol) - "A single topical drop of 0.002% OMDI significantly lowers IOP in normal and FCG cats without inducing miosis. Our findings support that topical selective EP2 agonists may be a promising therapeutic option for feline glaucoma and provide information relevant to dosing intervals for future studies."

Journal • Glaucoma • Ophthalmology

Benefit of omidenepag isopropyl ophthalmic solution in treatment persistence in Japanese patients with glaucoma. (PubMed, Sci Rep) - No abstract available

Journal • Glaucoma • Ophthalmology

Myopic Shift Induced by Omidenepag Isopropyl 0.002% in Patients with Primary Open-Angle Glaucoma. (PubMed, J Glaucoma) - "OMDI 0.002% eyedrops were associated with a notable incidence of myopic shift in patients with POAG. Ciliary muscle spasm is a possible underlying mechanism of myopic shift."

Journal • Glaucoma • Ophthalmology

Effects of Omidenepag Isopropyl Versus Latanoprost Eye Drops on Intraocular Pressure, Pupil Diameter, and Anterior Chamber Parameters in Normal Feline Eyes: A Pilot Study. (PubMed, Vet Ophthalmol) - "OMDI effectively reduced IOP in cats for at least 4 h without reducing PD. An increase in the CCA and mid-CCW, observed exclusively with OMDI, suggests that the hypotensive effect may be mediated by the conventional outflow pathway. Additionally, an increase in CMT in both the OMDI- and latanoprost-treated eyes may indicate an effect on the uveoscleral outflow pathway."

Journal • Glaucoma • Ophthalmology

Effectiveness and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution in Treatment-Naive Patients With Primary Open Angle Glaucoma: A Prospective Multicenter Phase IV Study. (PubMed, J Glaucoma) - "Omidenepag isopropyl 0.002% ophthalmic solution is suitable for first-line use at first diagnosis of POAG, including in patients with NTG."

Journal • P4 data • Glaucoma • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis

Omidenepag Isopropyl-Associated Cystoid Macular Edema After Trabeculectomy. (PubMed, JAMA Ophthalmol) - No abstract available

Journal • Macular Edema • Ophthalmology

Prostaglandin EP2 Receptor and Cystoid Macular Edema in Phakic Posttrabeculectomy Eyes. (PubMed, JAMA Ophthalmol) - "Omidenepag isopropyl (OMDI), a prostaglandin EP2 receptor agonist, effectively reduces intraocular pressure but has a known risk of cystoid macular edema (CME), particularly in pseudophakic and aphakic eyes...Cystoid macular edema can develop after initiating OMDI in patients with phakic eyes with a history of trabeculectomy prior to initiating OMDI. Further studies would be needed to understand the magnitude of this association and risk factors for this finding."

Journal • Glaucoma • Macular Edema • Ophthalmology

Safety and Efficacy of Omidenepag Isopropyl for Elevated Intraocular Pressure: A Systematic Review and Meta-Analysis. (PubMed, Am J Ophthalmol) - "OMDI 0.002% offers an alternative to FPs for IOP management especially when FPs may not be effective or suitable. While its efficacy is comparable, clinicians must consider the increased risk of AEs with OMDI. Short follow-up periods constrained the assessment of long-term efficacy and rare AEs; however, the absence of eyelash-related changes and prostaglandin associated periorbitopathy offers a cosmetic advantage over FPs. Further research could identify patient subgroups who may benefit from OMDI treatment."

Journal • Retrospective data • Review • Glaucoma • Ophthalmology

The Clinical Efficacy of a Topical Selective EP2 Receptor Agonist Against Feline Glaucoma That Is Not Responsive to Conventional Anti-Glaucoma Eyedrops. (PubMed, Vet Ophthalmol) - "OMDI could be an additional therapeutic option for feline glaucoma that is unresponsive to conventional therapies. Administration of OMDI following the early diagnosis of glaucoma is recommended to maximize therapeutic efficacy."

Journal • Cardiovascular • Cataract • Glaucoma • Hypertension • Ocular Inflammation • Ophthalmology • Uveitis

Objective hyperemia and intraocular pressure changes following omidenepag isopropyl application. (PubMed, PLoS One) - "One eye in the new administration group that developed macular edema during the observation period resolved spontaneously upon discontinuing omidenepag isopropyl. Both hyperemia and IOP reduction with omidenepag isopropyl ophthalmic solution were comparable to those achieved with F-prostanoid receptor agonists."

Journal • Observational data • Glaucoma • Macular Edema • Ophthalmology

Effectiveness and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution in Treatment-Naïve Patients with Primary Open-Angle Glaucoma: A Prospective Multicenter Phase IV Study. (PubMed, J Glaucoma) - "Omidenepag isopropyl 0.002% ophthalmic solution is suitable for first-line use at first diagnosis of POAG, including in patients with NTG."

Journal • P4 data • Glaucoma • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. (GlobeNewswire) - "Onconetix, Inc...and Ocuvex Therapeutics, Inc...today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex...Onconetix and Ocuvex will continue negotiations to enter into a definitive agreement. Upon closing of the proposed transaction, Onconetix will acquire all the issued and outstanding equity interests of Ocuvex in exchange for newly issued shares of common stock of Onconetix. Immediately following the closing of the proposed transaction, the pre-closing Ocuvex equity holders will own approximately 90% of the equity interests in Onconetix."

M&A • Glaucoma

Bioequivalence of Preservative-Free and Preserved Omidenepag Isopropyl 0.002% Ophthalmic Solutions in Patients With Primary Open Angle Glaucoma or Ocular Hypertension: Phase 3 DAISY Study. (PubMed, J Glaucoma) - "Preservative-free DE-117B and BAK-containing OMDI were bioequivalent in lowering IOP after 4 weeks' treatment in Japanese patients with POAG or OHT. DE-117B was well tolerated with a similar safety profile to OMDI."

Clinical • Journal • P3 data • Cardiovascular • Glaucoma • Ophthalmology

Pathogenic role of Thy-1 in prostaglandin-associated periorbitopathy (ARVO 2025) - "3T3-L1 cells were treated with dimethyl sulfoxide (control), 1 μM bimatoprost (BIMA), or 1 μM omidenepag isopropyl (OMDI, negative control) for 48 hours. Our study found that bimatoprost increases Thy-1 expression, driving orbital cells toward a myofibroblast fate that causes tissue tightening. These results suggest a pathological role for Thy-1 in severe PAP and provide insights for potential therapeutic strategies."

Ophthalmology • ACTA2 • THY1

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys. (PubMed, Transl Vis Sci Technol) - "Neither OMD nor OMDI interacted with the target receptors or enzymes of other antiglaucoma agents, suggesting that OMD interacts highly selectively with EP2 receptors. OMDI is a specific antiglaucoma agent that interacts selectively with ocular EP2 receptors."

Journal • Preclinical • Glaucoma • Ophthalmology

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial. (PubMed, Clin Ophthalmol) - P3 | "Most AEs were mild, with no serious ocular AEs. OMDI safely and effectively reduces IOP in Asian subjects with OAG/OHT, with mean diurnal IOP at Month 3 and per-timepoint IOP reductions non-inferior to those of latanoprost."

Clinical • Journal • P3 data • Cardiovascular • Glaucoma • Ophthalmology